Biotech Archives - Page 78 of 795

1 minute read

Amylyx Pharmaceuticals To Host Virtual Webcast To Discuss Interim Data From Phase 2 HELIOS Study Of AMX0035 In Wolfram Syndrome On April 10, 2024

April 8, 9:01 AM

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) ("Amylyx" or the "Company") today announced the Company will host a virtual webcast with management and Fumihiko Urano, MD, PhD, Principal Investigator of the HELIOS clinical

AMLX

6 minute read

Longeveron Issues Letter To Shareholders Highlighting Corporate Strategy, Clinical Pipeline And 2024 Key Priorities And Goals

By Benzinga Newsdesk

April 8, 8:44 AM

Longeveron Inc. (NASDAQ:LGVN), a clinical stage biotechnology company developing regenerative medicines, today announced that the Company's CEO, Wa'el Hashad, issued the following letter to Longeveron

LGVN

2 minute read

Nuvectis Pharma’s NXP900 Demonstrates Robust Activity In Non-Small Cell Lung Cancer Cell Lines

By Benzinga Newsdesk

April 8, 8:41 AM

Highly Synergistic Antiproliferative Activity in EGFR-resistant Cells in Combination with Osimertinib, the Active Ingredient in TagrissoTMSingle Agent Antiproliferative Activity in Cells Resistant to Alectinib, the

NVCT

1 minute read

CorMedix Inc. Announces 5-Year Contract With Dialysis Provider, ARC Dialysis For The Supply Of DefenCath

By Benzinga Newsdesk

April 8, 8:41 AM

CorMedix Inc. (NASDAQ:CRMD), a biopharmaceutical company focused on developing therapeutic products for life-threatening diseases and conditions, today announced that it has entered into a 5-year commercial supply

CRMD

3 minute read

NRx Pharmaceuticals Announces Data-Lock Of Phase 2b/3 Trial Of NRX-101 In Suicidal Treatment Resistant Bipolar Depression; With Data From This Study And FDA Comment, NRx Becomes Eligible To Receive The Balance Of Its First Milestone Of An Additional $4…

By Benzinga Newsdesk

April 8, 8:37 AM

Data transferred for independent statistical analysisTop-line data expected in April 2024RADNOR, Pa., April 8, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) ("NRx Pharmaceuticals", the "Company"), a

NRXP

2 minute read

Coherus Presents Preclinical Data For CHS-1000, A Novel Anti-ILT4 Antibody, At The 2024 AACR Annual Meeting

By Benzinga Newsdesk

April 8, 8:34 AM

– In preclinical studies, CHS-1000 shows a high affinity for human ILT4, reverses ILT4-mediated immunosuppressive functions, leading to activation of immune cells and increased cytokine secretion –– Mechanism may enhance

CHRS

2 minute read

Entera Bio Announces Publication Of Oral PTH(1-34) Peptide Tablets (EB613) Phase 2 Trial Data I1n The Journal Of Bone And Mineral Research

By Benzinga Newsdesk

April 8, 8:33 AM

Entera Bio Ltd. (NASDAQ:ENTX), ("Entera" or the "Company") a leader in the development of orally delivered peptides, announced today that data from the Phase 2 Trial of its lead clinical compound, EB613 (Oral PTH(1-34)

ENTX

2 minute read

Savara To Present New Data On Autoimmune Pulmonary Alveolar Proteinosis At The American Thoracic Society International Conference 2024

By Benzinga Newsdesk

April 8, 8:28 AM

Savara's Partner, Trillium Health LLC, to Present Data on the Laboratory Blood Test for Diagnosing aPAPCompany to Host Industry Theater on Pulmonary Alveolar Proteinosis (PAP) with Two World-Renowned ExpertsSavara Inc.

SVRA

2 minute read

C4 Therapeutics Presents New Preclinical Data For CFT1946 Highlighting Superior Activity As A Single Agent To Clinically Approved BRAF Inhibitor Standard Of Care Combinations At The American Association For Cancer Research Annual Meeting 2024

By Benzinga Newsdesk

April 8, 8:25 AM

C4 Therapeutics, Inc. (C4T) (NASDAQ:CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, presented a poster today at the American Association for Cancer Research

CCCC

2 minute read

Amarin Highlights Key Data Providing Mechanistic Insights Into Eicosapentaenoic Acid At ACC.24

By Benzinga Newsdesk

April 8, 8:23 AM

Amarin Corporation plc (NASDAQ:AMRN) today highlighted three data presentations at ACC.24 showcasing the mechanistic activity of Eicosapentaenoic acid (EPA), including the potential effects of EPA on

AMRN